Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894

Reuters2026/08/11 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Phio Pharmaceuticals received a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL siRNA designed to selectively silence BRD4.
The company framed the patent as strengthening IP protection for PH-894’s chemical structure, genetic sequencing, and potential uses in proliferative and infectious diseases.
Phio reported its patent portfolio totals 54 issued patents across INTASYL chemistry, gene targets, and therapeutic applications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 202608110700NEWSFILECNPR____20260811_309064_1) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894

You may also like

Crypto prices